Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAMP: Alpha-1 MP PK Comparability
NCT00295061Phase 3Completed
- Sponsor
- Grifols
- Start
- May 2006
- Primary completion
- Feb 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Grifols. Primary endpoint: Area Under the Curve from Day 0 to Day 7. Started May 2006; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00295061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295061.